Physician profile
Alaleh Akhavan
NPI 1205114709
$7,123.40
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,402 · 2020: $5,071 · 2021: $651.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $6,605.82 | 2019-2021 | |
| Abbvie INC. | $159.24 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $88.29 | 2019-2021 | |
| Leo Pharma INC. | $49.91 | 2019 | |
| Janssen Biotech, INC. | $26.00 | 2020 | |
| Melinta Therapeutics, LLC | $24.83 | 2019 | |
| Sun Pharmaceutical Industries INC. | $24.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.91 | 2019 | |
| Pfizer INC. | $22.90 | 2019 | |
| Celgene Corporation | $21.54 | 2019 | |
| Mylan Pharmaceuticals INC. | $21.12 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $19.69 | 2019 | |
| Genzyme Corporation | $18.95 | 2019 | |
| Promius Pharma LLC | $17.69 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaleh Akhavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.